IDYA
IDEAYA BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive near-term clinical readouts combined with at least one strategic partnership that extends cash runway and validates IDEAYA's biomarker-driven approach would materially de-risk the pipeline, enable multiple expansion, and could push the stock toward the bull target (~$79) seen among upper-end analyst estimates.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Competitive advances that diminish market opportunity for IDEAYA's programs
Momentum
26
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $49.00 · Bull $79.00 · Bear $25.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-08 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $50.06
Why
Momentum26 · Δ7d +8.8
Value41 · Δ7d +0.1
Sentiment100 · Δ7d 0.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
26
34% active weight
Current posture
7d trendImproving
Δ7d
+8.8
Δ21d
+16.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade B. Momentum 26.2 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$2.45B
Beta
0.10
Shares Out
87.67M
P/E (TTM) · Derived
-21.7
P/S (TTM)
14.26
P/FCF (TTM) · Derived
-23.45
Rev YoY
+78.5%
EPS YoY
+321.1%
Gross Margin
-
Op Margin
-97.2%
Net Debt
-$676.32M
Current Ratio
12.44
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology